[24] reported in a cohort of 106 ASCT patients aged 17–67 years old, with haematologic neoplasms, solid tumours and autoimmune diseases, that the time to platelet count recovery was significantly shorter in the group with a high post‐thaw CD34 dose (≥3 × 106 cell/kg) than that with a lower dose (<1.5 × 106 cell/kg). The gene discussed is CD34; the disease is hematopoietic and lymphoid cell neoplasm.